We are live on ! Find out more
GCM

Glenview Capital Management Portfolio holdings

AUM $5.49B
1-Year Est. Return 46.89%
This Fund
S&P 500
This Quarter Est. Return
+30.41%
1 Year Est. Return
+46.89%
3 Year Est. Return
+94.27%
5 Year Est. Return
+129.04%
10 Year Est. Return
+529.98%
AUM
$5.49B
AUM Growth
+$1.51B
Cap. Flow
+$309M
Cap. Flow %
5.62%
Top 10 Hldgs %
60.68%
Holding
58
New
14
Increased
15
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$240M
2
TMO icon
Thermo Fisher Scientific
TMO
+$181M
3
DHR icon
Danaher
DHR
+$180M
4
GPN icon
Global Payments
GPN
+$175M
5
META icon
Meta Platforms (Facebook)
META
+$143M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$301M
2
AMD icon
Advanced Micro Devices
AMD
+$144M
3
DXC icon
DXC Technology
DXC
+$112M
4
GTM
ZoomInfo Technologies
GTM
+$95.1M
5
CNC icon
Centene
CNC
+$71M

Sector Composition

Rank Sector Weight
1 Healthcare 49.86%
2 Industrials 12.99%
3 Technology 12.58%
4 Consumer Discretionary 9.03%
5 Miscellaneous 8.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSCO icon
26
Cisco
CSCO
$433B
$48.5M 0.88%
413,332
+73,513
+22% +$7.69M
ESI icon
27
Element Solutions
ESI
$8.51B
$47.5M 0.86%
994,579
-634,104
-39% -$26.3M
AMAT icon
28
Applied Materials
AMAT
$366B
$47.1M 0.86%
65,201
-132,008
-67% -$60.9M
MKSI icon
29
MKS Inc
MKSI
$17.3B
$43.8M 0.8%
+98,532
New +$30.8M
FUN icon
30
Cedar Fair
FUN
$1.66B
$43M 0.78%
2,017,821
-205,328
-9% -$4.19M
STM icon
31
STMicroelectronics
STM
$44B
$41.9M 0.76%
+560,060
New +$33.7M
ABBV icon
32
AbbVie
ABBV
$451B
$37.5M 0.68%
+148,913
New +$32M
AZN icon
33
AstraZeneca
AZN
$252B
$34.9M 0.64%
+184,279
New +$34.7M
BLCO icon
34
Bausch + Lomb
BLCO
$6.13B
$31.8M 0.58%
1,918,148
+7,652
+0.4% +$122K
BKR icon
35
Baker Hughes
BKR
$62B
$27.4M 0.5%
493,519
+189,844
+63% +$12M
ELV icon
36
Elevance Health
ELV
$85.5B
$25.8M 0.47%
+66,599
New +$24.7M
MCHP icon
37
Microchip Technology
MCHP
$39.6B
$24.2M 0.44%
+265,577
New +$23.7M
A icon
38
CALL
Agilent Technologies
A
$43.4B
$15.5M 0.28%
+116,600
New +$14.2M
BRKR icon
39
Bruker
BRKR
$8.7B
$15.2M 0.28%
+252,169
New +$11.8M
NVS icon
40
Novartis
NVS
$292B
$13.6M 0.25%
+86,909
New +$13M
DOCN icon
41
DigitalOcean
DOCN
$13.1B
$13.3M 0.24%
84,812
-165,188
-66% -$22.3M
PRMB
42
Primo Brands
PRMB
$8.32B
$9.9M 0.18%
404,971
-126,080
-24% -$2.8M
BSX icon
43
Boston Scientific
BSX
$67.9B
$4.83M 0.09%
+113,096
New +$6.14M
CAH icon
44
Cardinal Health
CAH
$54.6B
$4.28M 0.08%
+18,018
New +$3.74M
TECH icon
45
Bio-Techne
TECH
$11.3B
$4.12M 0.08%
58,324
-127,988
-69% -$6.91M
AKAM icon
46
Akamai
AKAM
$15.4B
– –
-156,453
Closed -$18M
BIIB icon
47
Biogen
BIIB
$32.3B
– –
-57,019
Closed -$10.5M
DXC icon
48
DXC Technology
DXC
$1.79B
– –
-8,895,875
Closed -$112M
GPN icon
49
CALL
Global Payments
GPN
$24.3B
– –
-100,000
Closed -$6.73M
INTC icon
50
Intel
INTC
$473B
– –
-399,506
Closed -$17.6M
1
2
3

Similar funds

GCM
Graham Capital Management Rowayton, Connecticut $5.5B AUM 26.66% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MC
Maplelane Capital New York $5.51B AUM 67.92% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Glenview Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Glenview Capital Management held 58 positions worth $5.49B, up 38% from $3.98B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Glenview Capital Management deployed $309M of net new capital in Q2 2026, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Agilent Technologies: 1,969,541 shares worth $262M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 45% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was CVS Health, an estimated $301M trimmed.

  • Glenview Capital Management's largest Q2 2026 buy was Agilent Technologies: 1,969,541 shares worth $262M.
  • Glenview Capital Management added most to Thermo Fisher Scientific in Q2 2026, an estimated $181M increase.
  • Glenview Capital Management's biggest Q2 2026 reduction was CVS Health, cutting an estimated $301M.
  • Glenview Capital Management fully exited DXC Technology in Q2 2026, selling an estimated $112M.
  • Glenview Capital Management's ten largest holdings make up 61% of its $5.49B portfolio in Q2 2026.
  • Glenview Capital Management opened 14 new positions and closed 13 in Q2 2026.
  • Glenview Capital Management's portfolio value rose 38% quarter-over-quarter to $5.49B.

Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.